key: cord-0270231-9u1uwkfz
authors: Hasan, Muhammad M.; Stebbins, Erin E.; Choy, Robert K.M.; Gillespie, J. Robert; de Hostos, Eugenio L.; Miller, Peter; Mushtaq, Aisha; Ranade, Ranae M.; Teixeira, José E.; Verlinde, Christophe L. M. J.; Sateriale, Adam; Zhang, Zhongsheng; Osbourn, Damon M.; Griggs, David W.; Fan, Erkang; Buckner, Frederick S.; Huston, Christopher D.
title: Spontaneous selection of Cryptosporidium drug resistance in a calf model of infection
date: 2021-01-18
journal: bioRxiv
DOI: 10.1101/2021.01.04.425361
sha: 9f84cf85a874619a7dd2793e7adf135d670300f4
doc_id: 270231
cord_uid: 9u1uwkfz

The intestinal protozoan Cryptosporidium is a leading cause of diarrheal disease and mortality in young children. There is currently no fully effective treatment for cryptosporidiosis, which has stimulated interest in anticryptosporidial development over the last ∼10 years with numerous lead compounds identified including several tRNA synthetase inhibitors. In this study, we report the results of a dairy calf efficacy trial of the methionyl-tRNA (CpMetRS) synthetase inhibitor 2093 and the spontaneous emergence of drug resistance. Dairy calves experimentally infected with Cryptosporidium parvum initially improved with 2093 treatment, but parasite shedding resumed in two of three calves on treatment day five. Parasites shed by each recrudescent calf had different amino acid altering CpMetRS mutations, coding either an aspartate 243 to glutamate (D243E) or a threonine 246 to isoleucine (T246I) mutation. Transgenic parasites engineered to have either the D243E or T246I CpMetRS mutation using CRISPR/Cas9 grew normally but were highly 2093 resistant; the D243E and T246I mutant expressing parasites respectively had 2093 EC50S of 613- or 128-fold that of transgenic parasites with wild-type CpMetRS. In studies using recombinant enzymes, the D243E and T246I mutations shifted the 2093 IC50 by >170-fold. Structural modeling of CpMetRS based on an inhibitor-bound Trypanosoma brucei MetRS crystal structure suggested that the resistance mutations reposition nearby hydrophobic residues, interfering with compound binding while minimally impacting substrate binding. This is the first report of naturally emerging Cryptosporidium drug resistance, highlighting the need to address the potential for anticryptosporidial resistance and establish strategies to limit its occurrence. Importance Cryptosporidium is a leading protozoan cause of diarrhea in young children with no reliable treatment. We report results of a dairy calf drug efficacy trial and the spontaneous emergence of drug resistance. Cryptosporidium parvum infected calves initially improved with drug treatment, but infection relapsed in two animals. Parasites shed by each recrudescent calf had mutations in the gene encoding the drug target that altered its amino acid sequence. Recapitulation of the drug target mutations by CRISPR/Cas9 genome editing resulted in highly drug-resistant parasites, and recombinant mutant enzymes were resistant to inhibition. This is the first report of naturally emerging Cryptosporidium drug resistance. There is a currently a great opportunity to impact public health with new drugs to treat cryptosporidiosis, and this report highlights the need to address the potential for anticryptosporidial resistance and establish strategies to limit its occurrence in order to realize their full potential. One-sentence summary Drug-target point mutations mediating anticryptosporidial resistance spontaneously arose in the dairy calf C. parvum infection model.

Infection of small intestinal epithelial cells with Cryptosporidium parasites causes the diarrheal illness cryptosporidiosis that in humans is mostly due either to Cryptosporidium hominis or Cryptosporidium parvum (1-4). Symptoms of cryptosporidiosis last twelve days on average in immunocompetent people but are often prolonged and potentially fatal in malnourished children and immunocompromised people, such as those with AIDS and transplant recipients (1). In addition to being a prominent cause of chronic diarrhea in AIDS patients, cryptosporidiosis was a leading cause of life-threatening diarrhea in children under two years of age in a landmark case-control study recently conducted at seven high-burden sites in Africa and the Indian subcontinent (5, 6) . Cryptosporidium infections are also strongly associated with childhood malnutrition, growth stunting, and delayed cognitive development (7, 8) .

Despite the large public health burden, no Cryptosporidium vaccine exists and treatments for cryptosporidiosis remain inadequate. Nitazoxanide is the only FDA-approved drug for cryptosporidiosis and is reliably efficacious only for immunocompetent adults for whom it shortens the duration of diarrhea by 1-2 days (9) . Unfortunately, nitazoxanide is no more effective than a placebo in HIV positive people, and data for young malnourished children are limited to small studies in which it appears at best modestly efficacious (10, 11) .

The need for improved anticryptosporidials motivated multiple drug development efforts employing both phenotypic and target-based methods over the last decade. These efforts have led to the identification of numerous promising lead compounds and two pre-clinical candidates that are poised for human studies (i.e. a Novartis phosphatidyl-inositol-4-kinase inhibitor and the 6-carboxamide benzoxaborole AN7973) (12) (13) (14) (15) (16) (17) (18) (19) (20) . There is the potential to realize an enormous public health benefit with intelligent deployment of improved anticryptosporidial drugs.

In many ways, the anticryptosporidial field evokes the situation for malaria shortly before the introduction of chloroquine in 1945, a time at which there was nearly a blank slate for treating malaria and the inevitability of drug resistance was not appreciated. Yet, chloroquine resistance first became evident for malaria around 1957, just twelve years after its release (21) .

Based on the hard lessons from malaria chloroquine resistance and antimicrobial resistance in general, combination therapy is now the standard for antimalarial development, as well as for treatment of numerous other infectious diseases where the risk of resistance is high (e.g. HIV and tuberculosis) (22) . This history stresses the need to understand the potential for Cryptosporidium drug resistance and how to best deploy new anticryptosporidials. To date, the possibility of anticryptosporidial resistance remains completely unexamined.

Aminoacyl-tRNA synthetase (aaRS) inhibitors are protein synthesis inhibitors with promise as potential treatments for bacterial, fungal, and parasitic infections. AaRS enzymes catalyze the formation of tRNAs charged with their corresponding amino acids that serve as the substrates for protein synthesis. Two aaRS inhibitors are already approved for human use: the topical anti-staphylococcal antibiotic mupirocin, a natural product that inhibits isoleucyl-tRNA synthetase (23) ; and tavaborole, a leucyl-tRNA synthetase inhibitor that is approved for topical treatment of onychomycosis (24, 25) . Beyond these topical agents, several aaRS inhibitors are in clinical trials as systemic antimicrobials, including a methionyl-tRNA synthetase (MetRS) inhibitor for treatment of Clostridium difficile infections (26) , a leucyl-tRNA synthetase (LeuRS) inhibitor for treatment of Gram-negative bacterial infections (27, 28) , and a LeuRS inhibitor for treatment of multidrug-resistant tuberculosis (29, 30) .

AaRS inhibitors figure prominently within the anticryptosporidial developmental pipeline (31) . Halofuginone, a prolyl-tRNA synthetase inhibitor, is approved for prevention and treatment of C. parvum infection in dairy cattle in Europe, but cannot be used in humans due to a narrow safety window (32) ; other prolyl-tRNA synthetase inhibitors are under study (16) .

Phenylalanyl-tRNA synthetase (PheRS) and Lysyl-tRNA synthetase (LysRS) inhibitors with promising activity in several mouse models of infection are also under development (14, 33) .

We previously reported that a MetRS inhibitor, 2093, potently inhibits the Cryptosporidium MetRS enzyme and is efficacious against C. parvum with no signs of toxicity in two murine models of infection (34) .

MetRSs are categorized into two forms based on sequence similarity: type I MetRSs We now report results of a 2093 drug efficacy trial performed in C. parvum infected dairy calves and the spontaneous emergence of MetRS inhibitor resistance. We identify two mutant parasite strains with different single amino acid substitutions in the C. parvum MetRS. We confirm C. parvum resistance to 2093 and further investigate the mechanism of resistance using a combination of CRISPR/Cas9 genome editing to modify the C. parvum MetRS (CpMetRS), in vitro enzymatic assays performed with recombinant mutant enzymes, and structural modeling.

This study is the first report of emergent Cryptosporidium drug resistance and, therefore, highlights a dire need to anticipate the potential for Cryptosporidium drug resistance and establish strategies to mitigate its development.

Neonatal dairy calves are highly susceptible to C. parvum infection and develop a selfresolving diarrheal illness that closely resembles cryptosporidiosis in young children.

Experimentally infected calves therefore provide a natural clinical model of C. parvum infection to determine both the microbiologic and clinical efficacy of drug leads (36, 37) . Based on promising results in both ifn-γ -/mice and NOD SCID gamma mice (34), we selected the MetRS inhibitor 2093 for testing in the calf model. We previously showed in a cell-based assay that the rate of C. parvum elimination by 2093 is maximized by exposure to concentrations at or above three times the EC90 (34) . A preliminary pharmacokinetics (PK) study performed on uninfected calves demonstrated plasma and fecal levels in excess of three times the EC90 for over 24 h following a single 10 mg per kg oral dose (Supplemental Fig. 1a ). To ensure 2093 levels in excess of three times EC90 despite possible reduced absorption and accelerated intestinal transit due to diarrhea, a dose of 15 mg per kg every 12 h was chosen for the efficacy study.

Bull Holstein calves were infected with ~5×10 7 C. parvum (Bunch Grass Farm Iowa isolate) at 24-48 h of age. 2093 or vehicle control treatments were begun on day two of infection, the time typically corresponding to the onset of diarrhea in this model (19, 37) , and continued for seven days (Fig. 1a) . Figure 1b shows the rate of oocyst shedding in the feces vs.

time for individual calves. 2093 initially appeared effective with progressive elimination of oocyst shedding from all treated calves during the first four days of infection. Total oocyst shedding, calculated as the area under the curve for each animal, was reduced nearly two logs during the first four days of compound treatment (Fig. 1c) . However, two of three 2093-treated calves relapsed with a progressive rise in fecal oocysts beginning on day four of treatment; the remaining calf appeared to be cured (Fig. 1b) . Recrudescence could not be attributed to inadequate dosing or altered drug levels in the presence of Cryptosporidium infection and diarrhea, since both fecal and plasma levels were well in excess of three times the EC90 beginning within 5 h of initiating treatment (Supplemental Fig. 1b) . These data suggested potential emergence of 2093-resistant parasites. It was impossible to isolate viable oocysts and test directly for drug resistance in vitro, because recrudescent C. parvum shedding was not recognized by qPCR until after sample freezing and euthanizing the animals.

Mutation of the target gene is one potential mechanism of acquired drug resistance, so the known target of 2093 provided an opportunity to investigate this possibility. For this, we used total DNA isolated from the feces of each vehicle and 2093-treated calf on experiment days 1 and 9 as PCR template, and Sanger sequenced the CpMetRS genomic locus. Predictably, no PCR product could be obtained from the cured calf on day 9. The genomic CpMetRS sequences on day 1 of the experiment were identical to the C. parvum Iowa strain gene sequence for all calves, but on day 9 each of the two relapsed calves had a distinct coding single nucleotide variant (SNV) in the CpMetRS gene (Supplemental Fig. 2 ). These variants were not present in the two control calves on day 9. The identified CpMetRS mutations were predicted to result in substitutions at amino acids 243 and 246 of the CpMetRS enzyme: aspartate 243 mutated to glutamate (D243E), and threonine 246 mutated to isoleucine (T246I) (Supplemental Fig. 2a) .

2093 treatment in the calf model therefore appeared to select for Cryptosporidium strains with two independent CpMetRS mutations that potentially conferred drug resistance.

We used a recently described method for CRISPR/Cas9 genome editing in C. parvum (38) to determine the effects of the amino acid altering CpMetRS mutations that were identified in the calf drug efficacy trial on parasite sensitivity to 2093. This method combines in vitro electroporation of a plasmid encoding the guide RNA and Cas9 enzyme, and a linear repair cassette, followed by infection of ifn-γ -/mice and in vivo selection of transgenic parasites with paromomycin. We engineered four transgenic C. parvum lines by replacing the parental CpMetRS locus with a transgene encoding wild-type CpMetRS or CpMetRSs with the D243E mutation, the T246I mutation, or both mutations in combination. The repair cassette was also designed to insert sequences for the enolase 3' untranslated region (UTR) for transcriptional termination of CpMetRS, and a fused nanoluciferase (Nluc)-neomycin phosphotransferase (Neo) under control of a constitutively active enolase promoter located just after the CpMetRS stop codon (Fig. 2a) . For each mutant parasite line, CpMetRS was recoded from base pairs 728 to 1686 to prevent homology directed repair without insertion of the selection marker. The recoded sequence also altered the gRNA recognition region to prevent repeated Cas9-mediated DNA cleavage (Fig. 2b) . Each transgenic parasite line was generated without difficulty and each was passaged once in NOD SCID gamma mice under paromomycin selection to remove potential parental contaminants before subsequent experiments. PCR using flanking primers demonstrated insertion of the repair cassettes at the endogenous locus with amplification of the respectively (Fig. 2c) . Sanger sequencing confirmed the successful introduction of each desired mutation (Fig. 2d ).

We next purified oocysts for each transgenic C. parvum line from mouse feces, and the in vitro growth rates and drug susceptibility of each parasite line were assessed using a high content microscopy-based assay for parasite development (39) . There were no significant differences in growth of the transgenic lines relative to Iowa strain C. parvum, as measured at 48 h post infection (Supplemental Fig. 3 ). The CpMetRS mutations had no effect on C. parvum 

The wild-type and two mutant CpMetRS genes were cloned, overexpressed in Escherichia coli, and purified for enzymatic studies. Enzymatic activity was confirmed in the aminoacylation assay (34) , which detects the esterification of radiolabeled methionine to the tRNA substrate. In order to measure the Michaelis-Menten constants for the enzymes, an ATP:PPi exchange assay was used, as previously explained (40) . First, looking at wild-type enzyme, the Km values for methionine and ATP were 31.3 and 1623 µM, respectively. These results are within a factor of ~2 of previously published results (34) . The Km values for the two mutant enzymes were considerably lower than for the WT enzyme (Table 1) , and the Kcat/Km values were higher, indicating greater catalytic efficiency. Next, the IC50 and Ki values of 2093 were determined for the three enzymes (Table 1) 

We previously solved multiple crystal structures of the Trypanosoma brucei (Tb) MetRS with inhibitors bound, including with 2093 (PDB: 6CML), which demonstrated that they inhibit enzymatic activity by competing with substrate binding (41) (42) (43) (44) . The CpMetRS and TbMetRS are 76% identical (19 of 25 amino acids) within the inhibitor binding pocket (34) , which presented the opportunity to further examine the mechanism of CpMetRS resistance to 2093.

We generated a CpMetRS model structure based on the T. brucei structures using I-TASSER (45) , and then docked compound 2093 into the model (Fig. 3 ). The predicted binding mode of 2093 to C. parvum MetRS shows the 2-chloro,4-methoxy-benzyl positioned in the enlarged methionine substrate pocket and the 5-Cl-imidazo [4,5b] pyridine in the "auxiliary pocket" formed upon inhibitor binding (41, 42) (also explained in Materials and Methods). D243 forms a salt bridge with H63. This salt bridge is at 3.8 Å from both the C6 and C7 of the imidazo [4,5- b]pyridine bicyclic system. We hypothesize that the D243E mutation disrupts the side wall of the auxiliary pocket by virtue of its larger size, which would lead to less favorable binding of the inhibitor. T246 is within van der Waals distance of the F242 phenyl ring. The resistance mutation T246I probably leads to a clash with the phenyl ring and thereby causes local unfolding of the -helix it belongs to, thereby disrupting the back wall of the auxiliary pocket.

This study is important because it highlights the likelihood of Cryptosporidium drug resistance, which has thus far been neglected during anticryptosporidial drug development.

Resistance to the CpMetRS inhibitor 2093 arose after four days of drug exposure in the neonatal dairy calf model despite plasma and fecal concentrations well above the in vitro EC90 for 2093 (Supplemental Fig. 1b) . Two amino acid altering SNVs in CpMetRS emerged independently, a D243E mutation and a T246I mutation. CRISPR/Cas9 genome editing showed that these mutations confer high-level C. parvum resistance to 2093, while not significantly affecting parasite growth or susceptibility to nitazoxanide. In studies using recombinant enzymes, the D243E and T246I mutations shift the 2093 IC50 by >170-fold. Modeling based on solved TbMetRS crystal structures suggests that the resistance mutations reposition nearby hydrophobic residues, interfering with compound binding while minimally impacting substrate binding. Our data confirm that the anticryptosporidial activity of 2093 and its analogs occurs via competitive inhibition of CpMetRS, and, more importantly, demonstrate rapid emergence of drug resistant C. parvum mutants.

Drug resistance in our study resulted from two coding single nucleotide alterations in the CpMetRS. It is uncertain if parasites harboring these mutations were pre-existing in the large population of parasites used to initiate infection or arose by spontaneous mutation in the presence of selective drug pressure. Suggesting a mechanism of spontaneous mutation, the MetRS SNVs identified here are not reported in the 53 Cryptosporidium genomes currently available in CryptoDB (https://cryptodb.org/cryptodb/). There are also no MetRS inhibitors in agricultural use to which the C. parvum isolate used in our calf study may have been previously exposed.

Evolution of antimicrobial resistance through spontaneous mutation is favored by the presence of large numbers of organisms, which could provide an explanation for outgrowth of resistant strains in the calf model despite its previously documented efficacy in murine models.

For example, Gram-negative bacterial resistance with specific target mutations developed in three of fourteen people after only one day of treatment in a phase II human trial of the LeuRS inhibitor GSK2251052 (AN3365) for complicated urinary tract infections (27) . This occurred despite an inability to select for GSK2251052 resistance in mice, presumably due to lower numbers of organisms in the mouse model. In our calf study, peak oocyst shedding in each control animal ranged from 10 7 to 10 8 oocysts per gram of feces. This number is consistent with previous studies of C. parvum infected calves (19, 37) and, based on the approximate volume of feces produced by a calf with cryptosporidiosis, on the order of 10 10 to 10 11 oocysts are shed during a typical ten day experiment using this model (19, 37, 46) . If we look to another apicomplexan parasite, Plasmodium falciparum, the estimated number of C. parvum organisms in the calf model is in-line with the burden of organisms during acute falciparum malaria (estimated at 10 8 to 10 12 (47)), a scenario in which treatment failure due to newly derived resistance is well-documented during treatment with a single drug, e.g. with atovaquone (48).

Up to 1 in 10 5 malaria parasites develop resistance to atovaquone (49) , virtually guaranteeing the development of resistance on monotherapy. We also note that the simplistic view of microbial evolution described above ignores the potential for sexual recombination within the human host, a life cycle feature of Cryptosporidium species that distinguishes it from Plasmodium and provides an additional mechanism to generate genetic diversity in the face of selective pressure.

A key unknown for cryptosporidiosis is the number of organisms during a human infection, which may of course differ for different host groups (e.g. parasite numbers might be greater in AIDS patients than in immunocompetent hosts).

The types and number of mutations required to confer antimicrobial resistance is a specific characteristic of different drug classes and targets, and together with fitness costs resulting from resistance mutations determines the propensity for emergence of resistance to a given drug (22) . For example, S. aureus resistance to rifampin typically results from one of several single amino acid mutations in the RNA polymerase β subunit (rpoB) that emerge readily (50, 51) ; as a result, rifampin is not useful as monotherapy for S. aureus infections. Studies with a first-generation MetRS inhibitor, REP8839, showed resistance frequency rates for S. aureus in the same range as rifampin (10 -7 to 10 -8 over a 48 hour exposure) (52), suggesting a low barrier to resistance. The first-step REP8839 Staphylococcus resistance SNVs occurred in close proximity to the corresponding CpMetRS SNVs identified in this study (52) , and the effects of these SNVs on enzyme kinetics with the natural substrates (methionine and ATP) were small for In summary, these data demonstrate spontaneous emergence of drug resistant C. parvum during a dairy calf clinical efficacy trial of the CpMetRS inhibitor 2093. Resistance was mediated by CpMetRS mutations coding altered amino acids that appear to reduce compound binding with minimal effect on substrate binding. Rapid evolution of resistance was likely favored by the large burden of C. parvum in the dairy calf model; it remains unknown if other mechanisms mediating tolerance or resistance occurred that might have enabled parasite persistence and thereby facilitated emergence of highly resistant CpMetRS mutants. Our experience heightens concern about the inevitability of Cryptosporidium drug resistance. The anticryptosporidial field is poised for introduction of improved treatments in the next several years. With the goal of understanding how to best deploy these new treatments, we are now developing methods to systematically study anticryptosporidial drug resistance and identify approaches to impede its occurrence. parvum abundance per gram of fecal dry matter was measured using a previously validated qPCR assay (primers listed in Supplemental Table 1 ) (56) . The lower limit of detection for this qPCR assay is ~100 oocysts/g of dried feces.

Serum samples were analyzed by liquid chromatography-tandem mass spectrometry (LC/MS/MS), using compound spiked into control serum as a standard. Fecal compound 2093 was measured by homogenizing feces in PBS (0.1 g/mL) in a polypropylene tube and then further dilution prior to addition of an internal standard (enalapril) and acetonitrile protein precipitation. The supernatant was transferred to a fresh tube and dried using a speed vac.

Samples were then resuspended and analyzed by LC/MS/MS.

Oocyst DNA was prepared from fecal samples (as described above). The CpMetRS gene was Sanger sequenced on day 3 (3 vehicle calves, 3 treatment calves) and on day 9 (single surviving vehicle calf and 2 treatment calves which showed a relapse). The Day 9 samples from the treatment group which showed point mutations were then amplified from genomic DNA, gel purified using the QiaQuick Gel Extraction Kit, (Qiagen, NL), cloned into the AVA0421 plasmid (57) , and sequence verified.

A previously established high-content microscopy assay was used to measure activity of 

Transgenic C. parvum were generated using CRISPR/Cas9 genome editing and a previously reported method employing in vitro electroporation of excysted sporozoites followed by infection of ifn-γ -/mice and paromomycin selection (38) . Mouse experiments for generation of transgenic C. parvum were approved by the University of Vermont Institutional Animal Care and Use Committee (IACUC).

To generate the Cas9/guide RNA plasmid, the CpMetRS guide sequence was cloned into the BbsI restriction site of the plasmid Aldo-Cas9-ribo. For the repair construct, a synthetic 999 bp fragment of the recodonized version of the CpMetRS (starting from amino acid number 247) along with the 3'UTR sequence of the enolase gene (cgd5_1960) was purchased (GenScript, NJ, USA). The synthetic construct was PCR amplified to introduce desired mutations and the 5' homology region was introduced as an overhang in the forward primer. The enolase promoternluc-neomycin cassette was amplified from the vector Cplic3HAENNE provided by the Striepen Lab (Univ. of Pennsylvania) and the 3' homology region was added at the end of this construct as a primer overhang. A 40 bp sequence homology was introduced in the two above mentioned fragments during the PCR and they were ligated with the NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs; catalog number E5520S). The whole cassette was then amplified with the end primer set. Each re-codonized construct was cloned into pCR TM 4Blunt-TOPO vector (Invitrogen) and sequence verified. To transfect C. parvum, the repair cassette for each mutant was PCR amplified from this vector using the end primer set. All PCR primers are included in Supplemental Table 1 .

Cryptosporidium parvum Iowa strain oocysts were purchased from Bunch Grass Farm (Deary, ID), excysted by treatment with 10 mM hydrochloric acid (10 min at 37°C) and then 2 mM sodium taurocholate in PBS (10 min at 16°C), and electroporated with Cas9/guide plasmid and repair DNA template using a Lonza Nucleofector 4D electroporator and the previously reported protocol (38) . C57BL/6 ifn-γ -/mice (Jackson Laboratory) aged 4-6 weeks (n=2) were infected by injection of transfected sporozoites into an externalized loop of small intestine, and transgenic parasites were selected for by inclusion of paromomycin ( Gemini #400-155P, 20 g/liter) in the mouse drinking water. Fecal samples were collected from cages and luminescence measurements were performed as described previously (38) . Mouse feces containing transgenic parasites were then passaged by infection of NOD SCID gamma mice (Jackson Laboratory), which become chronically infected with C. parvum (15) . Oocysts were purified from these mice for subsequent experiments.

Primers complementary to the 5' homologous CpMetRS region and the CpMetRS 3'UTR (primers P1 and P2 in Supplemental Table 1 ) were used for PCR on fecal DNA from the infected NOD-SCID gamma mice to confirm the correct 5' and 3' integration events following homologous recombination. For this, total fecal DNA was purified using an E.Z.N.A. Stool DNA Kit (Omega Bio-Tek), according to the manufacturer's pathogen detection protocol except for inclusion of six freeze-thaw cycles in kit lysis buffer as a first step. Sanger sequencing was used to confirm incorporation of the desired mutations, and parasites were purified for use in dose-response assays by sucrose flotation followed by cesium chloride purification using a previously described protocol (58) . Mouse fecal pellets were collected every two hours for oocyst purification, which enhanced parasite viability by preventing desiccation.

The expression and purification of the CpMetRS proteins was performed as previously described (57) 

A 3D model for UNPROT amino acid sequence Q5CVN0 was constructed with I-TASSER (59) . A user specified template was provided using the crystal structure of Trypanosoma brucei MetRS in complex with inhibitor 1312 (2-((3-((3,5- dichlorobenzyl)amino)propyl)amino)quinolin-4(1H)-one, PDB: 4eg5, chain B) to ensure a conformation of the protein that possesses the "auxiliary pocket" seen with dozens of inhibitors of that type, not only with T.brucei MetRS (41, 42) but also the congeners of Brucella melitensis (60) and Staphylococcus aureus (unpublished, PDB: 4qrd, 4qre). The overall sequence identity between template and target was 37%, the similarity 53%; the sequence identity in the expected binding site is 76%). Because I-TASSER does not take into account the presence of the ligand manual rotamer adjustment for five amino acid residues in the ligand binding site was necessary (residues Y24, H63, T185, T242, R221) so that they were the same as in the T.brucei MetRS complex. shedding is plotted for individual animals (n=3 for each group). Note that 2 animals in the control group died on day 5 due to unrelated causes (one due to congenital bladder obstruction and one due to pneumonia). LOD indicates the limit of detection for the qPCR assay. Samples with negative PCR results are plotted at the LOD. (c) Total oocyst shedding per gram of feces during study days 2-6. The area under the curve (AUC) in excess of the qPCR LOD is plotted for each calf. Lines show mean and standard deviation. * indicates p = 0.005 (unpaired two-tailed t-test) for reduced oocyst shedding in 2093treated animals up to the point of recrudescence in two of the three treated calves. (e) Susceptibility of parental and transgenic C. parvum isolates to nitazoxanide (NTZ) (negative control) and 2093. Data are combined from at least two biological replicate experiments per stain. Curves were calculated using all data points, but only every other dose is plotted in order to reduce clutter on the graphs.

Cryptosporidium pathogenicity and virulence

Multi-locus analysis of human infective Cryptosporidium species and subtypes using ten novel genetic loci

A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium

Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study

Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study

Natural History of Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling Bangladeshi Children: Association with Severe Malnutrition

Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a metaanalyses study

Prevention and treatment of cryptosporidiosis in immunocompromised patients

Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial

High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial

A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis

The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box

Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis

Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis

A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis

Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum

The origins of antimalarial-drug resistance

Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms

Structural basis for the recognition of isoleucyladenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase

An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site

Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies

Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study

Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections

Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria

Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase

A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors

Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase

Bicyclic azetidines cure infection with the diarrheal pathogen Cryptosporidium by inhibiting parasite phenylalanyl-tRNA synthetase

Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection

Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes

Description of fecal shedding of Cryptosporidium parvum oocysts in experimentally challenged dairy calves

Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model

Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum

Drug repurposing screen reveals FDAapproved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth

Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity

Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection

Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness

Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors

Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against Trypanosoma brucei

I-TASSER server for protein 3D structure prediction

Number of Cryptosporidium parvum oocysts or Giardia spp cysts shed by dairy calves after natural infection

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

Variations in frequencies of drug resistance in Plasmodium falciparum

The emergence of antibiotic resistance by mutation

Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus

Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase

Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis

Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents

Cancer drug resistance: an evolving paradigm

Detection and quantification of Cryptosporidium in HCT-8 cells and human fecal specimens using real-time polymerase chain reaction

Immobilized metal-affinity chromatography protein-recovery screening is predictive of crystallographic structure success

Generating and Maintaining Transgenic Cryptosporidium parvum Parasites

The I-TASSER Suite: protein structure and function prediction

Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis

QXP: powerful, rapid computer algorithms for structurebased drug design

We are grateful to Colin McMartin for providing us with the QXP+ software. Funding: This work was supported by PATH with funding from the UK government (grant 300341-111), and National Institute of Health grant R01 AI143951 (CDH)

Author contributions: MMH: Conceptualization, methodology, validation, formal analysis, visualization, writing (original draft, review, and editing); ES: Conceptualization, methodology, formal analysis; RKMC: Conceptualization, writing (review and editing)

JRG: Methodology, validation, formal analysis, writing (original draft, review, and editing), visualization; ELdH: Conceptualization, writing (review and editing), funding acquisition; PM: Methodology, validation, writing (review and editing); AM: Methodology, validation, formal analysis, writing (original draft); RMR: Methodology, validation

ZZ: Methodology; DMO: Methodology; formal analysis; DWG: Methodology; formal analysis; EF: Writing (review and editing), supervision, funding acquisition; FSB: Conceptualization, methodology, writing (original draft, review and editing), supervision; funding acquisition; CDH: Conceptualization, methodology, formal analysis, visualization, writing (original draft